engleski

Autologous bone graft substitute containing autologous blood coagulum with rhBMP6 accelerates bone formation compared to commercial rhBMP2 on bovine collagen

The aim of this study was to compare bone formation acceleration of a novel biocompatible carrier device for bone healing consisting of rhBMP6 in autologous blood coagulum (ABC) with bovine collagen and rhBMP2, currently the most commonly used bone device in clinics. To test bone formation efficacy of implant we used the axillary subcutaneous assay in rats. The rhBMP6 in ABC and rhBMP2 on bovine collagen were tested at doses of 5 and 20 µg per implant in 20 rats (4 implants per group and time point). Animals were killed and scanned using lCT device at day 7, 14 and 35 following implantation. Acquired images were reconstructed and the amount of new bone volume (BV) was analysed by µCT and on histology sections stained by von Kossa and Goldner. BV was higher in rhBMP6 + ABC then rhBMP2 + bovine collagen on day 7 and day 14 at both doses (Figure 1). On day 14, ABC + rhBMP6 (5 µg) implant had around 6 times more BV then implant with rhBMP2 + collagen, while with 20 µg rhBMP6 it increased 8 times. Both rhBMP6 and rhBMP2 had similar BV on day 35 suggesting that rhBMP6 in ABC significantly accelerated bone formation at early time points following implantation. The BV was equally increased as determined by histomorphometric analysis of histology sections. Therefore, ABC is a novel autologous carrier for rhBMP6 creating a permissive environment for rapid bone formation compared to commercially available bone repair device containing rhBMP2.

BMP ; BMP carrier ; Bone morphogenetic proteins ; Bone regeneration ; Tissue engineering

nije evidentirano